International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: 10.5281/zenodo.12787834
Original Research Article
Magnesium Sulphate : A New Frontier in Prevention of Intraventricular Hemorrhage in Premature Newborns
Published
Oct. 31, 2024
Abstract

Introduction:Intraventricular haemorrhage (IVH) remains a catastrophic neurological complication with considerable mortality and neurodevelopmental disability in preterm neonates.Given that preterm birth is a major cause, many strategies have been put forth for its prevention . The newest on the present day list is Magnesium Sulphate (MgSo4).Aims and Objectives:To determine the effect of exposure of antenatal magnesium sulfate on intraventricular hemorrhage in premature newborns evaluated by cranial ultrasoundand other neonatal complications at birth.Materials and Methods: This prospective interventional study was conducted on 70 women admitted to labor room in the Department of Obstetrics and Gynaecology, Sawai Mansingh Medical College, Jaipur. Women with singleton pregnancy between 28 to 32 weeks gestational age with expected delivery within 24 hours were included. Groups were allocated using flipcoin method into cases and controls, and the treatment group was administered with Magnesium Sulphate. Neonatal complications were reported at birth. On day 7, cranial ultrasound was done to evaluate IVH and its Papile grading.Results: Our study concluded that the occurence of IVH was low in both groups, though there wasslightly higher occurence ofIVH in the group not receiving MgSO4compared to the groupreceiving MgSO4(11.4% vs 2.9%). HIE(22.9% vs 25.7%), RDS (20% vs 25.7%), ROP(0% vs 5.7%), Hydrocephalus (0% vs 5.7%), Neonatal seizures (5.7% vs 8.6%) and Neonatal mortality (8.6% vs 11.4%) were the neonatal outcomes reported among those administered MgSo4 and those not.Conclusion: This study contributes to the body of evidence indicating that prenatal MgSO4 use on a large scale might be advantageousin prevention of IVH in preterm neonates. It offers a great deal of promise to lessen neurocognitive impairment and safeguard the growing fetal brain.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
2863 Views
98 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved